Home Stock

Stock Research: AstraZeneca

Independent stock analysis through peer comparison: Get the 360° View as an objective basis for stock decision-making and explore the detailed ranks.

AstraZeneca

LSE:AZN GB0009895292
76
  • Value
    61
  • Growth
    78
  • Safety
    Safety
    23
  • Combined
    50
  • Sentiment
    74
  • 360° View
    360° View
    76
Unlock
What factors are driving this 360° View?
Subscribe to View
Company Description

AstraZeneca PLC is a biopharmaceutical company that discovers, develops, and commercializes prescription medicines. It operates in oncology, rare diseases, and biopharmaceuticals. In the last fiscal year, the company had a market cap of $216,842 million, profits of $44,415 million, revenue of $54,073 million, and 94,300 employees.

more

ANALYSIS: With an Obermatt 360° View of 76 (better than 76% compared with alternatives) for 2026, overall professional sentiment and financial characteristics for the stock AstraZeneca are very positive. The 360° View is based on consolidating four consolidated indicators, with all but one indicator above average for AstraZeneca. The consolidated Value Rank has an attractive rank of 61, which means that the share price of AstraZeneca is on the lower side compared with the typical size in indicators such as revenues, profits, and invested capital. This means the stock price is lower than for 61% of alternative stocks in the same industry. The consolidated Growth Rank has a good rank of 78, which means that the company experiences above-average growth momentum when looking at financial metrics such as revenue, profit, and invested capital growth, as well as stock returns. In addition, professional market sentiment is above average compared with other stock investment alternatives with a Sentiment Rank of 74. But the company’s financing is risky with a Safety rank of 23. This means 77% of comparable companies have a safer financing structure than AstraZeneca. ...read more

more
Strongest Rank Refinancing
Weakest Rank Profit Growth
Country United Kingdom
Industry Pharmaceuticals
Size XX-Large
Website astrazeneca.com
Index
FTSE All Shares
FTSE 100
FTSE 350
NASDAQ
OMX 30
Renewables Users
AstraZeneca stock price by TradingView. Not sourced by Obermatt.
Similar Add to Watchlist Similar See Similar Stocks
The higher the 360° View, the better the stock performed against its peers, considering all metrics. The 360° View represents an average of the other 5 ranks and is then scaled to a rank from 1 to 100. The shaded values are illustrative only.
Last update: 3-Sep-2026.

Make Sense of the Ranks

The higher, the better. For every stock, we judge its performance against its peers and rank it on a scale of 1 to 100. These ranks are percentiles: a rank of 75 means the company outperforms 75% of its peers in that specific area. The higher the rank, the better the stock stacks up against its peers.

Value
Identifies how good a value the stock is.
Good Value Expensive
Combined
Consolidated view across Value, Growth, and Safety.
Good Tread Carefully
Growth
Shows a company's growth potential.
High Growth Tough Times
Sentiment
Shows what the market thinks of a stock.
Positive Sentiment Skepticism
Safety
Safety
Assesses how financially secure a company is.
Well-Financed High Leverage
360° View
360° View
Holistic stock analysis: all key non-/financial metrics
Good Watch Out

Detailed and Historical Ranks

Deep dive into 15 detailed ranks and 3 years of history. Unlock the analysis.

Unlock Ranks

Unlock all 15 detailed ranks and historical data for more than 8,000 stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Value
61 46 43 60
Growth
78 48 73 81
Safety
Safety
23 7 10 47
Sentiment
74 45 88 90
360° View
360° View
76 23 53 90
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for more than 8,000 stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Analyst Opinions
55 69 78 67
Opinions Change
53 19 52 52
Pro Holdings
n/a 87 92 80
Market Pulse
37 35 35 59
Sentiment
74 45 88 90
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for more than 8,000 stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Value
61 46 43 60
Growth
78 48 73 81
Safety Safety
23 7 10 47
Combined
50 15 28 70
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for more than 8,000 stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Price vs. Sales (P/S)
53 26 28 44
Price vs. Earnings (P/E)
47 51 51 58
Price vs. Book (P/B)
43 18 15 34
Dividend Yield
70 71 74 70
Value
61 46 43 60
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for more than 8,000 stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Revenue Growth
58 55 67 76
Profit Growth
96 42 60 74
Capital Growth
52 37 64 53
Stock Returns
37 67 42 68
Growth
78 48 73 81
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for more than 8,000 stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Leverage
28 20 20 9
Refinancing
21 6 7 96
Liquidity
60 54 44 32
Safety Safety
23 7 10 47

Similar Stocks

Discover high‑ranked alternatives to AstraZeneca and broaden your portfolio horizons.

ZIGUP

LSE:ZIG
Country: United Kingdom
Industry: Specialized Consumer Services
Size: Medium
Full Stock Analysis

Costain

LSE:COST
Country: United Kingdom
Industry: Construction & Engineering
Size: Medium
Full Stock Analysis

4imprint

LSE:FOUR
Country: United Kingdom
Industry: Advertising
Size: Medium
Full Stock Analysis

Faes Farma

MCE:FAE
Country: Spain
Industry: Pharmaceuticals
Size: Medium
Full Stock Analysis

Frequently Asked
Questions

This is a high-quality, high-growth stock with positive sentiment. However, the financing is on the riskier side. It is best for a growth-focused investor willing to accept higher financial risk for potentially higher shareholder returns.

Obermatt provides unbiased stock analysis as a completely independent third party. We have no conflicts of interest with individual stock titles. Our data-driven analysis is based on algorithms honed over twelve years, giving you analysis that is free from personal bias and conflicts of interest.

The 360° View Rank indicates a company's overall performance across all major financial and non-financial metrics tracked by Obermatt. A 360° View Rank of 75 means the company is more well-rounded than 75% of similar companies. A high score indicates that the company is strong across the board; it is attractively priced, growing sustainably, financially stable, and well-regarded by the market. Learn more.

Become an Obermatt subscriber and see all of the similar stocks here.

OTHER FEATURES

Use the Platform to its Fullest

The Obermatt Advantage

Ready to Elevate Your Investing?
Get Started Today

Choose the Obermatt subscription that best fits your needs.


30-day money back guarantee. Your subscription will renew until you cancel it, which you can do at any time.

What Our Customers Say

See how Obermatt improved their investing:

Review us See More Google Reviews